Merck & Co Inc (MRK): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Merck ( MRK) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.1%. By the end of trading, Merck rose $0.50 (1.1%) to $45.49 on average volume. Throughout the day, 14,119,929 shares of Merck exchanged hands as compared to its average daily volume of 16,280,200 shares. The stock ranged in a price between $44.95-$45.62 after having opened the day at $45.23 as compared to the previous trading day's close of $44.99. Other companies within the Drugs industry that increased today were: Vermillion ( VRML), up 30.1%, Affymax ( AFFY), up 25.7%, XOMA ( XOMA), up 22.4% and Cormedix ( CRMD), up 14.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $136.6 billion and is part of the health care sector. The company has a P/E ratio of 19.8, above the S&P 500 P/E ratio of 17.7. Shares are up 9.9% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Merck a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, MediciNova ( MNOV), down 26.8%, Dendreon ( DNDN), down 15.0%, Transcept Pharmaceuticals ( TSPT), down 13.9% and Delcath Systems ( DCTH), down 13.3% , were all laggards within the drugs industry with Novartis ( NVS) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts